Partial Seizures
📧 Sign up to get email alerts when something new happens for Partial Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-04-20FDA Approved: FELBAMATE — Original Application (Taro Pharmaceuticals U.S.A., inc.)
FDA approves the original ANDA application for Felbamate from Taro Pharmaceuticals U.S.A., enabling a generic version of the antiepileptic d…
-
FDA label_change · 2017-03-23FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) from Novartis Pharmaceuticals Corporation, resulting in a labeling…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years [Phase 3]
Phase 3 trial evaluating pregabalin as add-on therapy for partial onset seizures in children aged 4-16; completed with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures [Phase 4]
Phase 4 trial in children with partial seizures assessed the efficacy, safety, and tolerability of oxcarbazepine monotherapy.
-
CLINICAL_TRIALS trial_result · 2016-10-31Clinical Trial Update: Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of levetiracetam for controlling partial seizures, with or without secondary gen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-08-16Clinical Trial Update: Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures. [Phase 3]
Phase 3 trial evaluating diazepam for management of refractory epilepsy in patients requiring intermittent medical intervention for acute re…
-
FDA approval · 2016-02-26FDA Approved: ZONISAMIDE — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approved a supplemental application for zonisamide (Exelan Pharmaceuticals) under ANDA077869. This action relates to the approved generi…
-
FDA approval · 2016-02-18FDA Approved: GABAPENTIN — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original generic application for gabapentin from ScieGen Pharmaceuticals, Inc., establishing a generic version of gabapenti…
-
FDA approval · 2015-12-23FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) by Supernus Pharmaceuticals, Inc.
-
FDA approval · 2015-11-12FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approved a supplemental application for Zonegran (zonisamide) submitted by Advanz Pharma (US) Corp.
-
FDA label_change · 2015-09-18FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for Sabril (vigabatrin) filed by Lundbeck Pharmaceuticals LLC, resulting in updated labeling for the…
-
FDA approval · 2015-09-11FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) from Supernus Pharmaceuticals, Inc.
-
FDA approval · 2015-04-24FDA Approved: ZONISAMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for Zonisamide by Sun Pharmaceutical Industries, Inc., indicating a regulatory modification for the …
-
CLINICAL_TRIALS trial_result · 2015-03-05Clinical Trial Update: Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures. [Phase 3]
This Clinical Trial Update reports the completion of a Phase 3 study evaluating long-term safety and efficacy of pregabalin in patients with…
-
FDA approval · 2015-01-20FDA Approved: OXCARBAZEPINE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical, Inc.'s supplemental application for oxcarbazepine under the ANDA.
-
CLINICAL_TRIALS trial_result · 2014-09-22Clinical Trial Update: Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures [Phase 2, Phase 3]
This clinical trial update reports on the safety and tolerability of intravenous SPM 927 as a replacement for oral SPM 927 in subjects with …
-
CLINICAL_TRIALS trial_result · 2014-09-22Clinical Trial Update: SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization [Phase 3]
A Phase 3 trial evaluating SPM 927 as adjunctive therapy for partial seizures (with or without secondary generalization) completed, sponsore…
-
CLINICAL_TRIALS trial_result · 2014-08-15Clinical Trial Update: Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures [Phase 3]
Phase 3 trial update evaluating the efficacy and safety of zonisamide for partial seizures. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2014-07-18Clinical Trial Update: Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients [Phase 3]
This update reports the completion of a Phase 3 trial evaluating eslicarbazepine acetate as add-on therapy for partial seizures in elderly p…
-
CLINICAL_TRIALS trial_result · 2014-07-14Clinical Trial Update: Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug [Phase 4]
Phase 4 trial evaluated whether continuing zonisamide as adjunctive therapy is more effective or safer than replacing the last added antiepi…
-
FDA approval · 2014-03-25FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for gabapentin from BluePoint Laboratories, granting approval of a generic version under ANDA077…
-
CLINICAL_TRIALS research · 2014-01-27Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.
A completed clinical trial evaluating the safety and efficacy of zonisamide as monotherapy or adjunctive therapy in adults with partial, gen…
-
CLINICAL_TRIALS trial_result · 2013-07-11Clinical Trial Update: Pregabalin Versus Levetiracetam In Partial Seizures [Phase 3]
Phase 3 trial comparing pregabalin to levetiracetam in partial seizures has completed with results posted in 2013.
-
CLINICAL_TRIALS withdrawal · 2013-04-04Clinical Trial Update: GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures [Phase 2]
A Phase 2 trial evaluating GW273225 as add-on therapy for partial seizures in epilepsy was withdrawn.
-
CLINICAL_TRIALS trial_result · 2013-02-07Clinical Trial Update: An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs) [Phase 2]
Phase 2 add-on study of E2007 in patients with refractory partial seizures uncontrolled with other anti-epileptic drugs has completed enroll…